Skip to content

Viatris VTRS Accounts Receivable

Accounts Receivable at other companies

Pfizer logo
PfizerPFE
$12.59B+6.2%
McKesson logo
McKessonMCK
$27.99B+9.1%
ANI Pharmaceuticals logo
ANI PharmaceuticalsANIP
$255.43M+15.9%
Cencora logo
CencoraCOR
$24.89B+5.0%
AMP
Amphastar PharmaceuticalsAMPH
$147.85M+2.2%
ARS Pharmaceuticals, Inc. logo
ARS Pharmaceuticals, Inc.SPRY
$28.66M+208%

Other financials

Income statement

See full
Revenue$3.5B+8.1%
Gross profit$1.2B-0.3%
Operating income-$79.7M+97.2%
Net income$176.4M+106%
EPS (diluted)$0.15+106%

Balance sheet

See full
Cash & equivalents$1.8B+139%
Total debt$14.6B+1.0%
Total equity$14.7B-6.3%
Total assets$36.8B-4.3%

Cash flow

See full
Operating cash flow$388.3M-27.5%
CapEx$39.9M-6.3%
Free cash flow$348.4M-29.3%

Valuation

See full
Market cap$20.8B+92.8%
Enterprise value$33.61B+34.5%
P/S1.4×+0.7×

Profitability

See full
Gross margin34.4%-2.5pp
Operating margin1%
Net margin-2%-1.0pp
FCF margin12.3%-1.0pp

Returns & leverage

See full
Return on equity-2%-0.9pp
Debt / equity+0.1×
Current ratio1.6×-0.1×

Where this comes from

Reported directly by Viatris in its filing.

Tagged under the XBRL concept us-gaap:ReceivablesNetCurrent.

The official record: Viatris’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Viatris's accounts receivable.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Viatris's accounts receivable?
Viatris (VTRS) reported accounts receivable of $2.58B in Q1 2026.
How has Viatris's accounts receivable changed year-over-year?
Viatris's accounts receivable decreased by 0.3% year-over-year, from $2.58B to $2.58B.
What is the long-term trend for Viatris's accounts receivable?
Over 4 years (2021 to 2025), Viatris's accounts receivable has grown at a -8.3% compound annual growth rate (CAGR), from $15.39B to $10.87B.
What does accounts receivable mean?
Amounts owed by customers for goods delivered or services performed, net of allowances for doubtful accounts. A key working capital component.